Gadoxetate disodium

Drug Profile

Gadoxetate disodium

Alternative Names: EOB Primovist; Eovist; gadolinium EOB DTPA; gadoxetic acid; Gd-EOB-DTPA; Primovist; ZK 139834

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Massachusetts General Hospital
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver disorders

Most Recent Events

  • 01 Apr 2017 Discontinued - Phase-III for Liver disorders (Diagnosis, In infants) in USA (IV), because not listed on Bayer pipeline, April 2017
  • 15 Dec 2016 Biomarkers information updated
  • 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top